A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker
机构：[1]Jilin Provincial Cancer Hospital(JPCH), Changchun, China[2]Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[3]307 Hospital of the Academy of Military Medical Sciences, Cancer Center, Beijing, China[4]Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China[5]The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[6]Third Affiliated Hospital Third Military Medical University of People's Liberation Army, Chongqing, China[7]Cancer Hospital of Harbin Medical University, Harbin, China[8]PLA Cancer Center of Nanjing Bayi Hospital, Nanjing, China[9]Hebei Tumor Hospital, Shijiazhuang, China河北医科大学第四医院[10]Fujian Provincial Tumor Hospital, Fuzhou, China[11]Tangdu Hospital, 4th Military Medical University, Xi'an, China[12]The Affiliated Hospital of Medical College Qingdao University, Qingdao, China[13]Linyi Tumor Hospital, Linyi, China[14]Shandong Cancer Hospital, Jinan, China
第一作者机构：[1]Jilin Provincial Cancer Hospital(JPCH), Changchun, China
推荐引用方式(GB/T 7714)：
Cheng Ying,Fan Yun,Liu Xiaoqing,et al.A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker[J].JOURNAL OF CLINICAL ONCOLOGY.2014,32(15):doi:10.1200/jco.2014.32.15_suppl.7595.
APA：
Cheng, Ying,Fan, Yun,Liu, Xiaoqing,Liu, Yunpeng,Liu, Jiwei...&Sheng, Lijun.(2014).A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.JOURNAL OF CLINICAL ONCOLOGY,32,(15)
MLA：
Cheng, Ying,et al."A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker".JOURNAL OF CLINICAL ONCOLOGY 32..15(2014)
医学